Zealand Pharma A/S (ZEAL)
Stock Price:
$35.85 USD
1.09 (3.14%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
1.42B |
| Revenue (ttm) |
5.82M |
| Net Income (ttm) |
89.15M |
| Shares Out |
39.67M |
| EPS (ttm) |
3.00 |
| PE Ratio |
11.95 |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$35.85 |
| Previous Close |
$34.76 |
| Change ($) |
1.09 |
| Change (%) |
3.14% |
| Day's Open |
35.40 |
| Day's Range |
35.29 - 35.88 |
| Day's Volume |
2,549 |
| 52-Week Range |
18.75 - 44.60 |
More Stats
| Market Cap |
1.42B |
| Enterprise Value |
1.24B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
39.67M |
| Float |
28.34M |
| EPS (basic) |
n/a |
| EPS (diluted) |
3.00 |
| FCF / Share |
3.20 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
8.37% |
| FCF Yield |
6.91% |
| Payout Ratio |
n/a |
| Shares Short |
78,812 |
| Short Ratio |
12.98 |
| Short % of Float |
n/a |
| Beta |
1.13 |
| PE Ratio |
11.95 |
| Forward PE |
n/a |
| P/FCF Ratio |
14.46 |
| PS Ratio |
244.16 |
| PB Ratio |
8.07 |
| Revenue |
5.82M |
| Operating Income |
100.06M |
| Net Income |
89.15M |
| Free Cash Flow |
98.32M |
| Net Cash |
177.80M |
| Net Cash / Share |
4.48 |
| Gross Margin |
100.00% |
| Operating Margin |
1,717.86% |
| Profit Margin |
1,530.60% |
| FCF Margin |
1,687.95% |
| ROA |
-26.71% |
| ROE |
-54.23% |
| ROIC |
294.20% |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (7)
| Buy |
6 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$43.07*
(20.14% upside)
Low
33.1
Current: 35.85
High
58.0
Target: 43.07
*Average 12-month USD price target from 7 stock analysts.
Financial Performance
Financial numbers in millions DKK.
Financial Overview
| Year | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | 37.98 | 136 | 231 | 183 |
| Revenue Growth | -72.14% | -40.95% | 26.45% | - |
| Gross Profit | 37.98 | 136 | 231 | 183 |
| Operating Income | 652 | -249 | -119 | -85.74 |
| Net Income | 581 | -275 | -157 | -118 |
| Shares Outstanding | 30.75 | 30.09 | 30.09 | - |
| Earnings Per Share | 18.94 | -9.88 | -6.47 | -5.13 |
| Operating Cash Flow | -460 | -279 | 40.90 | -225 |
| Capital Expenditures | 1,101 | -7.11 | -2.60 | -4.04 |
| Free Cash Flow | 641 | -286 | 38.30 | -229 |
| Cash & Equivalents | 1,159 | 664 | 323 | 419 |
| Total Debt | - | 136 | 332 | 313 |
| Net Cash / Debt | 1,159 | 528 | -8.91 | 106 |
| Assets | 1,230 | 721 | 683 | 628 |
| Liabilities | 114 | 207 | 416 | 383 |
| Book Value | 1,116 | 515 | 267 | 245 |
Numbers in millions DKK, except per-share numbers.
Company Details
| Full Name |
Zealand Pharma A/S |
| Country |
Denmark |
| Employees |
191 |
| CEO |
Emmanuel Dulac |
Stock Information
| Ticker Symbol |
ZEAL |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ZEAL |
| IPO Date |
August 9, 2017 |
Description
Zealand Pharma A/S, a biotechnology company, engages in the discovery and development of peptide-based medicines in Denmark. It has a portfolio of medicines in development stage focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes glepaglutide, a long acting GLP-2 analog, which is in Phase 3 clinical trials for the treatment of short bowel syndrome; and dasiglucagon, a stable glucagon analog for the treatment of severe hypoglycemia in diabetes and congenital hyperinsulinism, as well as for use in dual-hormone artificial pancreas for automated diabetes management. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; and Beta Bionics, Inc. to initiate home-use trial of the iLet bionic pancreas with dasiglucagon for autonomous bihormonal treatment of type 1 diabetes, as well as research agreement with Orbit Discovery Ltd. and Torrey Pines Institute for Molecular Studies. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.